Menu
T-25: Impact of US Breakthrough Therapy Designation on Approval Timelines of Drugs and Biologics in the EU
Poster Presenter
- Regulatory Affairs Postdoctoral Fellow, GlaxoSmithKline
- University of North Carolina
United States